Phreesia Stock Price, News & Analysis

Phreesia, a leader in patient intake and activation, has renewed its contract with the CMS Innovation Center (CMMI) for the use of the Patient Activation Measure® (PAM) through 2029. The PAM assesses patients' knowledge, skills, and confidence in managing their healthcare. This renewal follows the success of the Kidney Care Choices (KCC) Model, which aims to improve care for Medicare beneficiaries with chronic kidney disease.

The first annual evaluation of the KCC model revealed significant improvements, including:

• An average 8.8-point increase in PAM scores
• A 20% increase in home dialysis
• A 16% increase in optimal ESRD starts
• A 15% increase in patients on the transplant waitlist

These results demonstrate the effectiveness of patient activation in improving healthcare outcomes and reducing costs. Phreesia's continued partnership with CMMI may lead to expanded use of PAM in additional healthcare models and settings.

New research by Phreesia reveals that delivering digital vaccine-related messages to patients before medical appointments significantly increases vaccine uptake. The study, analyzing over 20.2 million digital vaccine messages across all 50 states between March 2020 and May 2024, found that patients exposed to point-of-care messages received vaccinations at a rate more than twice as high as control groups. Key findings include:

- 49% of patients said the information was new to them
- 65% were likely to discuss vaccines with their doctor
- In some cases, messaging drove vaccine administration rates more than 10X higher than the control group

The research demonstrates the effectiveness of providing timely, credible vaccine information in supporting vaccine confidence and adoption, even among historically marginalized populations and during periods of increased vaccine hesitancy.

The CDC has awarded a research grant to a joint project involving Phreesia, the National Association For Continence (NAFC), Health.Equity.Outcomes., and Dr. Christina Escobar to address the public health challenge of urinary incontinence (UI) in women. The project aims to raise awareness and empower women to seek treatment for UI, which affects nearly 100 million women in the U.S. but remains underdiagnosed and undertreated.

The initiative will leverage Phreesia's digital patient engagement platform to deploy a campaign encouraging women to discuss UI with their healthcare providers. The project will also focus on creating an indicator report on UI prevalence, developing survey questions, and publishing educational content on screening, prevention, and treatment options.

Phreesia (NYSE: PHR) reported strong financial results for Q2 fiscal 2025, ending July 31, 2024. Highlights include:

- Total revenue of $102.1 million, up 19% year-over-year
- Average healthcare services clients (AHSCs) of 4,169, up 21% year-over-year
- Net loss of $18.0 million, improved from $36.8 million loss in prior year
- Adjusted EBITDA of $6.5 million, up from negative $11.5 million
- Positive free cash flow of $3.7 million

The company maintained its fiscal 2025 revenue outlook of $416-426 million and raised Adjusted EBITDA guidance to $26-31 million. Phreesia expects continued growth in AHSCs and revenue per AHSC through fiscal 2026.

Phreesia, a patient intake and activation leader, has partnered with the American Academy of Pediatrics (AAP) to boost measles, mumps, and rubella (MMR) vaccination rates among children. The campaign targets caregivers of children aged 9 months to 6 years who haven't completed the MMR series. It will run on Phreesia's digital intake platform, providing educational content about AAP recommendations for MMR immunization.

The collaboration aims to address the dip in immunization rates, with the national MMR vaccination rate for kindergartners at 93%, below the 95% threshold for community immunity. AAP recommends the first MMR vaccine between 12-15 months and a second dose at 4-6 years. The campaign leverages Phreesia's platform, which enabled about 150 million patient visits in 2023, to deliver important vaccination information at the point of care.

Phreesia, a leader in patient intake, outreach and activation, has named Bob Glazer as a Strategic Advisor. Glazer, with over 45 years of healthcare leadership experience, is currently the President of Glazer Business Advisors. He previously served as CEO of ENT and Allergy Associates (ENTA) for 27 years, growing it from 12 to 250 providers across 50+ locations. Phreesia COO Evan Roberts expressed excitement about Glazer's appointment, citing his understanding of medical practices' on-the-ground reality. Glazer aims to help the next generation of physicians and views his advisory role at Phreesia as a means to achieve this goal. Phreesia, founded in 2005, enabled approximately 150 million patient visits in 2023, representing more than 1 in 10 visits across the U.S.

Phreesia (NYSE: PHR) has announced the release date for its fiscal second quarter 2025 financial results. The company will publish its quarterly results and stakeholder letter after market close on Wednesday, September 4, 2024. A conference call to discuss the results will follow at 5 PM Eastern Time. Investors can participate by dialing (800) 715-9871 (US) or (646) 307-1963 (international) using code 7404611. The call will also be available via webcast on Phreesia's investor website.

Phreesia, founded in 2005, is a leader in patient activation, providing tools for healthcare providers, life sciences companies, and payers. In 2023, the company facilitated approximately 150 million patient visits, representing over 10% of U.S. healthcare visits. Phreesia offers digital solutions for patient intake, outreach, and education to enhance patient experience and improve healthcare outcomes.

Phreesia, a leader in patient intake and activation, has announced its availability on Oracle Healthcare Marketplace, integrating with Oracle Health Electronic Health Record (EHR). This collaboration enhances Phreesia's existing integration with Oracle, offering expanded benefits for customers. Organizations using Oracle Health EHR can now leverage Phreesia's suite of solutions, including appointment scheduling, patient registration, consent management, revenue cycle management, clinical intake workflows, and referral management.

Phreesia has achieved Oracle's Industry Healthcare Expertise validation, highlighting its commitment to serving Oracle Health customers. In 2023, Phreesia enabled approximately 150 million patient visits, representing more than 1 in 10 visits across the U.S. This integration aims to enhance patient experience, drive efficiency, and improve healthcare outcomes.

Phreesia, in collaboration with the National Kidney Foundation, has published new research in The American Journal of Accountable Care, highlighting the importance of patient-provider discussions and patient activation for the early diagnosis and treatment of chronic kidney disease (CKD). The study surveyed 4,445 patients with diabetes and/or hypertension and revealed that two-thirds of these high-risk patients were unaware of their risk for CKD. Key findings showed that 70% of highly activated diabetic patients discussed kidney health with their provider, compared to 38% of low-activation patients. Similarly, 51% of highly activated hypertensive patients had these discussions compared to just 7% of their low-activation counterparts. The research emphasizes that patient activation and frequent patient-provider conversations are vital in encouraging preventive health behaviors. Phreesia's ability to deliver personalized messages at the point of care aims to improve patient awareness and engagement, potentially leading to better health outcomes.